ESC 365 - A pre-specified, participant-level pooled analysis of PARAGON-HF and PARAGLIDE-HF

HFA Premium Access

A pre-specified, participant-level pooled analysis of PARAGON-HF and PARAGLIDE-HF

Session: Late breaking clinical trials: medical therapy

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Speaker: Doctor M. Vaduganathan (Boston, US)

Event: Heart Failure 2023

Congress Presentation

Add to my library

About the speaker

Doctor Muthiah Vaduganathan

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

36 presentations

11 followers

4 more presentations in this session

PARAGLIDEHF: Sacubitril/Valsartan versus valsartan on changes in NTproBNP, safety, and tolerability in patients with EF>40% stabilized after a WHF Event

Speaker: Doctor R. Mentz (Durham, US)

STEP HFpEF trial design and baseline characteristics

Speaker: Doctor M. Kosiborod (Kansas City, US)

DAPA-RESIST clinical trial - Dapagliflozin versus metolazone in heart failure with diuretic resistance

Speaker: Doctor R. Campbell (Glasgow, GB)

Verinurad plus allopurinol for heart failure with preserved ejection fraction: results from the AMETHYST randomized controlled trial

Speaker: Professor A. Voors (Groningen, NL)

Access the full session

Late breaking clinical trials: medical therapy

Speakers: Doctor M. Vaduganathan, Doctor R. Mentz, Doctor M. Kosiborod, Doctor R. Campbell, Professor A. Voors

About the event

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources